Viking reports Q2 2026 results, VANQUISH trials fully enrolled, oral Phase 3 slated for 4Q26
Viking Therapeutics said its two subcutaneous VK2735 Phase 3 obesity trials are fully enrolled while it prepares to start an oral Phase 3 program and ended the quarter with $502 million in cash.
Viking Therapeutics reported second quarter 2026 financial results and a pipeline update on July 29, 2026. The company said its Phase 3 VANQUISH-1 and -2 trials are fully enrolled and proceeding according to plan.1 VANQUISH-1 reached roughly 4,500 patients by November 2025, and enrollment in the VANQUISH-2 study was completed in the first quarter, enrolling approximately 1,000 patients.1 Both trials assess subcutaneous VK2735 administered once weekly for 78 weeks1 against placebo, with the primary endpoint being percent change in body weight from baseline after 78 weeks.
On the oral formulation, Viking said it continued to prepare for initiation of Phase 3 trials with the oral formulation of VK2735, expected to begin in the fourth quarter of this year.1 The company separately said it expects to report results from its VK2735 maintenance dosing study, a Phase 1 trial exploring weekly, every-other-week and monthly regimens, later in the third quarter of 2026, as previously guided.
Viking also disclosed progress on a second obesity candidate. VK3019 is an investigational dual amylin and calcitonin receptor agonist (DACRA) in development for the potential treatment of obesity.1 After filing an IND in the first quarter of 2026, following clearance of the IND, in the second quarter the company initiated a Phase 1 single ascending dose (SAD) clinical trial evaluating VK3019.1
On leadership, Viking said the company in the second quarter announced the appointment of Hubert Chen, M.D., as chief medical officer,1 and following the end of the second quarter, the company appointed Dorothy Gemmell to its board of directors.1
Financially, at June 30, 2026, Viking held cash, cash equivalents and short-term investments of $502 million, compared to $706 million as of December 31, 2025.1 For the quarter, Viking reported a net loss of $128.0 million, or $1.10 per share, compared to a net loss of $65.6 million, or $0.58 per share, in the corresponding period in 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.